KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Shares Outstanding (Weighted Average) (2020 - 2025)

Historic Shares Outstanding (Weighted Average) for Royalty Pharma (RPRX) over the last 6 years, with Q4 2025 value amounting to $429.8 million.

  • Royalty Pharma's Shares Outstanding (Weighted Average) fell 410.19% to $429.8 million in Q4 2025 from the same period last year, while for Dec 2025 it was $429.8 million, marking a year-over-year decrease of 410.19%. This contributed to the annual value of $429.8 million for FY2025, which is 410.19% down from last year.
  • Per Royalty Pharma's latest filing, its Shares Outstanding (Weighted Average) stood at $429.8 million for Q4 2025, which was down 410.19% from $431.9 million recorded in Q3 2025.
  • In the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) registered a high of $451.0 million during Q2 2024, and its lowest value of $389.8 million during Q1 2021.
  • Its 5-year average for Shares Outstanding (Weighted Average) is $435.3 million, with a median of $437.1 million in 2022.
  • Per our database at Business Quant, Royalty Pharma's Shares Outstanding (Weighted Average) soared by 1573.82% in 2021 and then plummeted by 477.94% in 2025.
  • Over the past 5 years, Royalty Pharma's Shares Outstanding (Weighted Average) (Quarter) stood at $414.8 million in 2021, then grew by 5.59% to $438.0 million in 2022, then rose by 2.2% to $447.6 million in 2023, then increased by 0.13% to $448.2 million in 2024, then fell by 4.1% to $429.8 million in 2025.
  • Its Shares Outstanding (Weighted Average) was $429.8 million in Q4 2025, compared to $431.9 million in Q3 2025 and $429.5 million in Q2 2025.